These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2772886)

  • 1. [It won't be a duty to prescribe the cheapest synonymous agent].
    Gadeholt G
    Tidsskr Nor Laegeforen; 1989 Aug; 109(22):2179-80. PubMed ID: 2772886
    [No Abstract]   [Full Text] [Related]  

  • 2. [The cheapest synonymous preparation--a suggestion with unwanted consequences. Is it the cheapest drugs?].
    Rytter E
    Tidsskr Nor Laegeforen; 1989 Aug; 109(22):2178-9. PubMed ID: 2772885
    [No Abstract]   [Full Text] [Related]  

  • 3. "Disinformation" from pharmaceutical company representatives.
    Gordon M
    CMAJ; 1990 Jun; 142(11):1177-8. PubMed ID: 2344567
    [No Abstract]   [Full Text] [Related]  

  • 4. Personalized medicine: challenges in assessing and capturing value in the commercial environment.
    Ferrara J
    Expert Rev Mol Diagn; 2006 Mar; 6(2):129-31. PubMed ID: 16512770
    [No Abstract]   [Full Text] [Related]  

  • 5. Are drugs interchangeable?
    Drummond G
    Lancet; 2000 Jan; 355(9200):316; author reply 317-8. PubMed ID: 10675095
    [No Abstract]   [Full Text] [Related]  

  • 6. Genesis of generic drugs.
    Calesnick B; Kreider LA; Dinan A
    Pa Med; 1986 Dec; 89(12):32, 34, 36. PubMed ID: 3808720
    [No Abstract]   [Full Text] [Related]  

  • 7. [The cheapest synonymous preparations--a proposal with unwanted consequences].
    Jacobsen TK
    Tidsskr Nor Laegeforen; 1989 Jun; 109(16):1807-9. PubMed ID: 2749660
    [No Abstract]   [Full Text] [Related]  

  • 8. [Relationship between clinical pharmacology and pharmaceutical industry].
    Ponec K
    Cas Lek Cesk; 1973 Jun; 112(26):821-8. PubMed ID: 4718381
    [No Abstract]   [Full Text] [Related]  

  • 9. The economics of drug prescribing in Ireland.
    O'Hanrahan M; O'Malley K
    Ir Med J; 1981 Oct; 74(10):309-10, 312. PubMed ID: 7309452
    [No Abstract]   [Full Text] [Related]  

  • 10. [Should we chose the cheapest, essentially similar drug?].
    Caamaño F; Figueiras A; Pardo De Vera G
    Gac Sanit; 2001; 15(3):287-8. PubMed ID: 11423038
    [No Abstract]   [Full Text] [Related]  

  • 11. Substitution--the relevant market.
    Chappell SC
    Med Mark Media; 1981 Sep; 16(9):54, 56. PubMed ID: 10252449
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of generics is driving up prices of single-source drugs.
    Fine J
    Mod Healthc; 1986 Nov; 16(24):48. PubMed ID: 10279441
    [No Abstract]   [Full Text] [Related]  

  • 13. The medical profession and the pharmaceutical industry: when will we open our eyes?
    Woodruff TG
    Med J Aust; 2004 Oct; 181(8):458. PubMed ID: 15487968
    [No Abstract]   [Full Text] [Related]  

  • 14. [The carrot and the stick for physicians and pharmacists. A questionable model for the Bavaria contract on reducing the price of drug therapy].
    Girstenbrey W
    Fortschr Med; 1984 Jun; 102(24):72-3. PubMed ID: 6469183
    [No Abstract]   [Full Text] [Related]  

  • 15. Polymorphism in generic drug product development.
    Snider DA; Addicks W; Owens W
    Adv Drug Deliv Rev; 2004 Feb; 56(3):391-5. PubMed ID: 14962588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug substitution, savings, and safety.
    Lancet; 1982 Sep; 2(8299):640. PubMed ID: 6125781
    [No Abstract]   [Full Text] [Related]  

  • 17. Current product equivalency issues.
    Gerrard TL
    Food Drug Law J; 1995; 50(3):451-3. PubMed ID: 10343011
    [No Abstract]   [Full Text] [Related]  

  • 18. The medical profession and the pharmaceutical industry: when will we open our eyes?
    Masters S
    Med J Aust; 2004 Oct; 181(8):459; discussion 459. PubMed ID: 15612086
    [No Abstract]   [Full Text] [Related]  

  • 19. High-tech drug development will contain health costs.
    Zenner P
    Med Mark Media; 1982 Feb; 17(2):10, 12, 14 passim. PubMed ID: 10309544
    [No Abstract]   [Full Text] [Related]  

  • 20. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.